SCHEMBL1711035

SCHEMBL1711035

CC(C)(C)OC(=O)c1ccc(NCc2ccccc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.73
CA2 P00918 3/20 0.73
HDAC3 O15379 1/20 0.52
HDAC1 Q13547 1/20 0.52
HDAC2 Q92769 1/20 0.52
NCOR2 Q9Y618 1/20 0.52
FFAR1 O14842 1/20 0.50
FFAR4 Q5NUL3 1/20 0.50
HTT P42858 1/20 0.50
HIF1A Q16665 3/20 0.49
ABCG2 Q9UNQ0 1/20 0.49
ALDH1A1 P00352 3/20 0.48
MAPT P10636 2/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
NAMPT P43490 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CA12 O43570 1/20 0.48
CA7 P43166 1/20 0.48
CA14 Q9ULX7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15876086 0.87 HIF1A (0.58) CA1CA2HIF1AALDH1A1MAPT
SCHEMBL28124357 0.86 CA1 (0.69) CA1CA2HDAC3HDAC1HDAC2
SCHEMBL17308777 0.86 CA1 (0.80) CA1CA2HDAC3ALDH1A1MAPT
SCHEMBL1711043 0.86 HDAC1 (0.59) CA1CA2HDAC1FFAR1HTT
SCHEMBL2190706 0.85 HIF1A (0.55) CA1CA2FFAR1HIF1AABCG2
SCHEMBL18415526 0.84 CA1 (1.00) CA1CA2HDAC3HDAC1HDAC2
SCHEMBL16355719 0.84 CA1 (0.57) CA1CA2FFAR1FFAR4HIF1A
SCHEMBL3129145 0.84 ALDH1A1 (0.57) CA1CA2HTTALDH1A1MAPT
SCHEMBL3291794 0.82 CA1 (0.53) CA1CA2HDAC3HDAC1HDAC2
SCHEMBL3129375 0.82 CA1 (0.51) CA1CA2ABCG2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112979510-A Sulfonamide compounds and their use as STAT5 inhibitors 多伦多大学管理委员会 2021-06-18 CN disclosed
EP-3148967-B1 SULFONAMIDE COMPOUNDS AND THEIR USE AS STAT5 INHIBITORS GOVERNING COUNCIL UNIV TORONTO (CA) 2019-10-02 EP disclosed
EP-3148967-B1 SULFONAMIDE COMPOUNDS AND THEIR USE AS STAT5 INHIBITORS GOVERNING COUNCIL UNIV TORONTO (CA) 2019-10-02 EP disclosed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-20170101369-A1 SULFONAMIDE COMPOUNDS AND THEIR USE AS STAT5 INHIBITORS THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2017-04-13 US disclosed
US-20170101369-A1 SULFONAMIDE COMPOUNDS AND THEIR USE AS STAT5 INHIBITORS THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2017-04-13 US disclosed
US-20170101369-A1 SULFONAMIDE COMPOUNDS AND THEIR USE AS STAT5 INHIBITORS THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2017-04-13 US disclosed
EP-3148967-A1 SULFONAMIDE COMPOUNDS AND THEIR USE AS STAT5 INHIBITORS The Governing Council of the University of Toronto (CA) 2017-04-05 EP disclosed
WO-2015179956-A1 SULFONAMIDE COMPOUNDS AND THEIR USE AS STAT5 INHIBITORS THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2015-12-03 WO disclosed
WO-2015179956-A1 SULFONAMIDE COMPOUNDS AND THEIR USE AS STAT5 INHIBITORS THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2015-12-03 WO disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP disclosed
US-7714000-B2 Substituted pyrrolidinones and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-05-11 US disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed
US-20060217435-A1 New Substituted Pyrrolidinones and Their Use as Medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 CA1 2149/4885CA2 337/4885HDAC3 448/4885
US-20060217435-A1 New Substituted Pyrrolidinones and Their Use as Medicaments PYCR1, S100A9, REV1 CA1 2387/4885CA2 727/4885HDAC3 4513/4885
US-20170101369-A1 SULFONAMIDE COMPOUNDS AND THEIR USE AS STAT5 INHIBITORS STAT5A, STAT5B, JAK2 CA1 3070/4885CA2 2340/4885HDAC3 995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.